146 related articles for article (PubMed ID: 3988975)
1. Interethnic dissociation between debrisoquine and desipramine hydroxylation.
Rudorfer MV; Lane EA; Potter WZ
J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975
[TBL] [Abstract][Full Text] [Related]
2. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
Spina E; Steiner E; Ericsson O; Sjöqvist F
Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
[TBL] [Abstract][Full Text] [Related]
3. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.
Spina E; Steiner E; Dumont E; Dahlqvist R
Psychopharmacol Ser; 1989; 7():201-5. PubMed ID: 2687858
[No Abstract] [Full Text] [Related]
5. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
[TBL] [Abstract][Full Text] [Related]
6. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians.
Mahgoub A; Idle JR; Smith RL
Xenobiotica; 1979 Jan; 9(1):51-6. PubMed ID: 760321
[TBL] [Abstract][Full Text] [Related]
7. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
Kallio J; Lindberg R; Huupponen R; Iisalo E
Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
[TBL] [Abstract][Full Text] [Related]
8. Polymorphic 2-hydroxylation of desipramine. A population and family study.
Dahl ML; Iselius L; Alm C; Svensson JO; Lee D; Johansson I; Ingelman-Sundberg M; Sjöqvist F
Eur J Clin Pharmacol; 1993; 44(5):445-50. PubMed ID: 8359181
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
Sommers DK; Moncrieff J; Avenant J
Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
[TBL] [Abstract][Full Text] [Related]
11. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Du YL; Lou YQ
Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
[TBL] [Abstract][Full Text] [Related]
12. Genetically determined oxidation capacity and the disposition of debrisoquine.
Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
[TBL] [Abstract][Full Text] [Related]
13. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators.
Steiner E; Spina E
Clin Pharmacol Ther; 1987 Sep; 42(3):278-82. PubMed ID: 3621781
[TBL] [Abstract][Full Text] [Related]
14. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Alván G; Grind M; Graffner C; Sjöqvist F
Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
[TBL] [Abstract][Full Text] [Related]
15. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.
Nordin C; Siwers B; Benitez J; Bertilsson L
Br J Clin Pharmacol; 1985 Jun; 19(6):832-5. PubMed ID: 4027124
[TBL] [Abstract][Full Text] [Related]
16. Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals.
Kalow W; Otton SV; Kadar D; Endrenyi L; Inaba T
Can J Physiol Pharmacol; 1980 Sep; 58(9):1142-4. PubMed ID: 7459706
[TBL] [Abstract][Full Text] [Related]
17. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
Yue QY; Svensson JO; Alm C; Sjöqvist F; Säwe J
Br J Clin Pharmacol; 1989 Dec; 28(6):639-45. PubMed ID: 2611086
[TBL] [Abstract][Full Text] [Related]
18. Debrisoquine hydroxylation capacity: problems of assessment in two populations.
Inaba T; Otton SV; Kalow W
Clin Pharmacol Ther; 1981 Feb; 29(2):218-23. PubMed ID: 7460485
[TBL] [Abstract][Full Text] [Related]
19. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
Sanz EJ; Bertilsson L
Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
[TBL] [Abstract][Full Text] [Related]
20. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
